<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7283535 doi: 10.3389/fimmu.2020.01048 : Immunology: Review Vaccines Against Antimicrobial" exact="Resistance" post="RosiniRoberto1NicchiSonia12PizzaMariagrazia2RappuoliRino134*[], 1GSKSienaItaly[], 2Department of Pharmacy and Biotechnology (FaBiT), University"/>
 <result pre="that have contributed to the cure and prevention of many" exact="infectious diseases." post="The era of antimicrobial therapy started in the nineteenth"/>
 <result pre="number of resistant microorganisms. Rapid spreading of mobile elements by" exact="horizontal" post="gene transfer such as plasmids and integrative conjugative elements"/>
 <result pre="the impact of AMR on life expectancy and economics. vaccines" exact="infectious diseases" post="antimicrobial resistance (AMR) vaccine development vaccinology mechanisms of antibiotic"/>
 <result pre="expectancy has generally been between 25 and 35 years with" exact="infection" post="diseases being the balance needle. The living conditions of"/>
 <result pre="effective medical interventions to reduce mortality and morbidity caused by" exact="infectious diseases." post="In fact, in the poor areas of our planet"/>
 <result pre="antibiotics and vaccination are not well-established, life expectancy is still" exact="lower" post="than 50 years (2). Vaccination has protected humans by"/>
 <result pre="the control of 16 major diseases, namely, smallpox, diphtheria, tetanus," exact="yellow fever," post="pertussis, Haemophilus influenzae type b disease, poliomyelitis, measles, mumps,"/>
 <result pre="type b disease, poliomyelitis, measles, mumps, rubella, typhoid, rabies, rotavirus," exact="hepatitis" post="B, pneumococcal, and meningococcal diseases. Noteworthy is the complete"/>
 <result pre="rotavirus, hepatitis B, pneumococcal, and meningococcal diseases. Noteworthy is the" exact="complete" post="or partial eradication achieved for smallpox and poliomyelitis, respectively"/>
 <result pre="B, pneumococcal, and meningococcal diseases. Noteworthy is the complete or" exact="partial" post="eradication achieved for smallpox and poliomyelitis, respectively (3). To"/>
 <result pre="diseases. Noteworthy is the complete or partial eradication achieved for" exact="smallpox" post="and poliomyelitis, respectively (3). To counteract infectious diseases, the"/>
 <result pre="eradication achieved for smallpox and poliomyelitis, respectively (3). To counteract" exact="infectious diseases," post="the discovery of antimicrobial treatment was another significant milestone"/>
 <result pre="the discovery by Alexander Fleming of a new class of" exact="non-toxic" post="antimicrobial agents derived from environmental fungi gave rise to"/>
 <result pre="drugs are therapeutics with different modes of action targeting the" exact="bacterial" post="functions such as cell wall integrity, nucleic acid synthesis"/>
 <result pre="the most daunting problems that is causing the spread of" exact="infectious diseases" post="and the increase in the number of deaths caused"/>
 <result pre="and the increase in the number of deaths caused by" exact="infections" post="that were previously considered uncomplicated (7). For example, the"/>
 <result pre="that were previously considered uncomplicated (7). For example, the bloodstream" exact="infections" post="caused by bacteria resistant to one or several drugs"/>
 <result pre="50% of mortality compared with the 24% of the non-multidrug-resistant" exact="infections" post="(8). In addition, medical procedures such as surgeries, immunosuppressive"/>
 <result pre="the consequences of such microbial evolution can be dramatic with" exact="infectious diseases" post="that could severely reduce our lifespan to an extent"/>
 <result pre="a number even, higher than the 8.2 million caused by" exact="cancer" post="today (9) (Figure 2). Figure 1 Life expectancy increase"/>
 <result pre="vaccines as a means of treatment and prevention of many" exact="infectious diseases." post="Figure 2 Number of deaths and the main causes"/>
 <result pre="and the projection of number of deaths due to AMR" exact="infections" post="in 2050 (in red in the Right). Gray areas"/>
 <result pre="the Right). Gray areas represent other causes of deaths. Antibiotic" exact="Resistance" post="Mechanisms and Prioritization of Antibiotic Resistant Microorganisms Antibiotic resistance"/>
 <result pre="thus reducing antimicrobial effectiveness and raising the incidence of severe" exact="disease" post="(11). However, this is not a new phenomenon and"/>
 <result pre="to their spread. The first classification is between natural and" exact="acquired" post="resistance mechanisms. The natural resistance relies on the bacterial"/>
 <result pre="and acquired resistance mechanisms. The natural resistance relies on the" exact="bacterial" post="ability to block the antibiotic function as a result"/>
 <result pre="to get access to the d-Ala-d-Ala peptides. By contrast, the" exact="acquired" post="resistance is based on the gaining of new functions;"/>
 <result pre="as Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis, but also" exact="Acinetobacter" post="spp. and Pseudomonas aeruginosa (Figure 3A) (24). Lastly, aminoglycoside-modifying"/>
 <result pre="from broiler chickens in China (25) and more recently in" exact="Group B" post="streptococcus (26). Yet, the prevention of antibiotic access to"/>
 <result pre="which results in a decrease in antibiotics entry into the" exact="bacterial" post="cell. Porins are beta barrel proteins that cross the"/>
 <result pre="in the antibiotic targets by mutation or post-translational modifications. (D)" exact="Resistance" post="mechanism of Mycobacterium tuberculosis to isoniazid drug mutations in"/>
 <result pre="by mutation or post-translational modifications. (D) Resistance mechanism of Mycobacterium" exact="tuberculosis" post="to isoniazid drug mutations in the katG gene causes"/>
 <result pre="toxic effects of antibiotics. Examples are provided by mutations in" exact="bacterial" post="DNA gyrases (e.g. gyrA) and topoisomerase (e.g. parC) for"/>
 <result pre="recombination frequency has subsequently enabled the allele enrichment in the" exact="bacterial" post="population. Another example of a target change is the"/>
 <result pre="a target change is the acquisition of specific genes by" exact="horizontal" post="gene transfer (HGT), such as in methicillin-resistant S. aureus"/>
 <result pre="target molecule. This is exemplified by the polymyxin resistance in" exact="Acinetobacter" post="baumanni (polymyxin B and polymyxin E, also known as"/>
 <result pre="(38). In 2019 an estimation performed by the Centers for" exact="Disease" post="Control and Prevention (CDC) in the United States reported"/>
 <result pre="the United States reported that more than 2.8 million antibiotic-resistant" exact="infections" post="occur in the U.S. each year, and more than"/>
 <result pre="list) (39). These bacteria can cause severe and often deadly" exact="infections" post="and have become resistant to a large number of"/>
 <result pre="disinfectants (40). In A. baumannii, &quot;resistance islands�? located on the" exact="bacterial" post="chromosomes and/or on mobile genetic elements induce a drug-resistant"/>
 <result pre="For example, AbaR1 is an 86kb resistance- island generated by" exact="recurrent" post="insertions of different mobile genetic elements, which can spread"/>
 <result pre="insertions of different mobile genetic elements, which can spread by" exact="horizontal" post="gene transfer (HGT) within the genera Pseudomonas, Salmonella, and"/>
 <result pre="lipid A and overexpression of the AdeABC efflux system (41)." exact="Tuberculosis" post="(TB), even if not initially included in the WHO"/>
 <result pre="negatively affects the outcome of TB-treatment facilitating the dissemination of" exact="MDR-TB" post="and reducing the efficacy of INH (44). The second"/>
 <result pre="the treatment of N. gonorrhoeae with sulfonamides, this bacterium has" exact="acquired" post="genetic resistance determinants capable to inhibit the killing by"/>
 <result pre="that are used as first line methods of treatment against" exact="gonorrhea" post="infection (47). The main lethal target of cephalosporins is"/>
 <result pre="are used as first line methods of treatment against gonorrhea" exact="infection" post="(47). The main lethal target of cephalosporins is the"/>
 <result pre="resistance has led the World Health Organization and Center for" exact="Disease" post="Control (US) to classify this bacterium as &quot;superbug.�? As"/>
 <result pre="be discovered soon, we may enter an era of incurable" exact="gonorrhea" post="infections (48). Therefore, understanding the mechanisms underlying the AMR"/>
 <result pre="discovered soon, we may enter an era of incurable gonorrhea" exact="infections" post="(48). Therefore, understanding the mechanisms underlying the AMR will"/>
 <result pre="killed by previously effective drugs through several mechanisms described above." exact="Resistance" post="is largely driven by the abuse of antibiotics in"/>
 <result pre="little or no therapeutic benefit. The use of antibiotics in" exact="viral" post="respiratory infections or abuse in animal care and in"/>
 <result pre="or no therapeutic benefit. The use of antibiotics in viral" exact="respiratory" post="infections or abuse in animal care and in agriculture"/>
 <result pre="no therapeutic benefit. The use of antibiotics in viral respiratory" exact="infections" post="or abuse in animal care and in agriculture to"/>
 <result pre="to cover all the key pathogens responsible for a particular" exact="infection" post="(50). Moreover, the relationships between the human microbiome and"/>
 <result pre="including penicillins, cephalosporins and carbapenems. This is particularly relevant for" exact="infections" post="caused by Gram-negative bacteria sensitive only to carbapenems, and"/>
 <result pre="the two Dutch travelers which were infected by a NDM-1-producing" exact="bacterial" post="strain during their trip to India, even if not"/>
 <result pre="centers (52). Enterobacteriaceae (Klebsiella pneumoniae, E. coli and Proteus mirabilis)," exact="Acinetobacter" post="spp. and Pseudomonas aeruginosa are the most common NDM-1-producing"/>
 <result pre="mcr-1 resistance determinant is able to easily spread in different" exact="bacterial" post="species and also worldwide due to business globalization (24)."/>
 <result pre="business globalization (24). Hence, the spread of resistant organisms, highly" exact="infectious" post="and inducing high rate of morbidity and mortality has"/>
 <result pre="measures since generally prescribed after the settling down of an" exact="infection" post="when hundreds of millions of bacteria are infecting the"/>
 <result pre="encountering the pathogen or even at the beginning of an" exact="infection" post="when only a few hundred or thousands bacteria are"/>
 <result pre="use of antimicrobial compounds. Perhaps counterintuitive is the evidence that" exact="viral" post="vaccines are also very effective in reducing AMR. For"/>
 <result pre="both, the inappropriate use of antibiotics prescribed in case of" exact="viral" post="infections and the need of antibiotic treatment to cure"/>
 <result pre="the inappropriate use of antibiotics prescribed in case of viral" exact="infections" post="and the need of antibiotic treatment to cure secondary"/>
 <result pre="viral infections and the need of antibiotic treatment to cure" exact="secondary" post="bacterial infections (59). (II) By reducing the insurgence of"/>
 <result pre="infections and the need of antibiotic treatment to cure secondary" exact="bacterial infections" post="(59). (II) By reducing the insurgence of resistant serotypes."/>
 <result pre="and the need of antibiotic treatment to cure secondary bacterial" exact="infections" post="(59). (II) By reducing the insurgence of resistant serotypes."/>
 <result pre="conjugate vaccine (PCV7), more than 63,000 cases of invasive pneumococcal" exact="disease" post="occurred each year in the US. Between 2000 and"/>
 <result pre="a 57% reduction in the incidence of penicillin-non-susceptible invasive pneumococcal" exact="disease" post="(IPD) and 84% reduction in the rate of multidrug-resistant"/>
 <result pre="These data indicate that vaccination is effective, regardless of the" exact="bacterial" post="resistance phenotype. However, the universal use of PCV-7 led"/>
 <result pre="or resistant strains is highly valuable (62). (III) By reducing" exact="infection" post="rate of resistant strains in closely related species. Between"/>
 <result pre="immunization with MeNZB resulted in 31% reduction of Neisseria gonorrhoeae" exact="infection" post="(63). N. gonorrhoeae is one of the most common"/>
 <result pre="infection (63). N. gonorrhoeae is one of the most common" exact="bacterial" post="sexually transmitted diseases (STDs), with ~100 million cases worldwide."/>
 <result pre="million cases worldwide. One of the main concerns of gonococcal" exact="infection" post="is the emergence of strains resistant to nearly all"/>
 <result pre="and the lack of an effective vaccine. Hence, N. gonorrhoeae" exact="infections" post="are becoming as the most prevalent and difficult to"/>
 <result pre="to evaluate the effectiveness of MenB-4C vaccine in preventing gonococcal" exact="infections" post="(66). (IV) By directly targeting antibiotic resistant microorganisms. Although"/>
 <result pre="Although many different vaccine formulations have been proposed to prevent" exact="infection" post="by antimicrobial resistant pathogens, (such as S. aureus, E."/>
 <result pre="virulence mechanisms a vaccine should target, as well as the" exact="absence of" post="animal models that are representative of human diseases (69,"/>
 <result pre="leading to the refinement of health care system against AMR" exact="infections" post="and eventually saving millions of lives. Modern Technologies and"/>
 <result pre="Vaccines Attempts to &quot;vaccinate�? begin even before the Edward Jenner's" exact="smallpox" post="vaccination was introduced. In the 7th century, some Indian"/>
 <result pre="of variolation, consisting in the introduction of dried pus from" exact="smallpox" post="pustules into the skin of a patient, was practiced"/>
 <result pre="in 1796 he tested the protective effect of a prior" exact="cowpox" post="infection against smallpox by actively immunizing an eight-year-old-boy with"/>
 <result pre="1796 he tested the protective effect of a prior cowpox" exact="infection" post="against smallpox by actively immunizing an eight-year-old-boy with cowpox"/>
 <result pre="tested the protective effect of a prior cowpox infection against" exact="smallpox" post="by actively immunizing an eight-year-old-boy with cowpox and then"/>
 <result pre="cowpox infection against smallpox by actively immunizing an eight-year-old-boy with" exact="cowpox" post="and then carrying out smallpox challenge (variolation) (72). In"/>
 <result pre="actively immunizing an eight-year-old-boy with cowpox and then carrying out" exact="smallpox" post="challenge (variolation) (72). In the 19th century, Louis Pasteur"/>
 <result pre="laboratory conditions, so that they induce immunity by simulating natural" exact="infections" post="causing no or very mild disease (73). Moreover, they"/>
 <result pre="immunity by simulating natural infections causing no or very mild" exact="disease" post="(73). Moreover, they provide a recurrent antigenic stimulation that"/>
 <result pre="no or very mild disease (73). Moreover, they provide a" exact="recurrent" post="antigenic stimulation that ensures memory cells production. An example"/>
 <result pre="developed in 1922. Killed microorganisms are safer, do not induce" exact="disease" post="and have an excellent stability profile, even if the"/>
 <result pre="and several doses of vaccine may be required. For many" exact="viral" post="diseases, the risk of reinfection is null due to"/>
 <result pre="the induction of antibodies directed against invariable antigens (e.g., smallpox," exact="yellow fever," post="polio, rabies, mumps, measles, rubella, varicella, herpes zoster, hepatitis"/>
 <result pre="(e.g., smallpox, yellow fever, polio, rabies, mumps, measles, rubella, varicella," exact="herpes zoster," post="hepatitis A, and Japanese encephalitis). Therefore, vaccines that were"/>
 <result pre="yellow fever, polio, rabies, mumps, measles, rubella, varicella, herpes zoster," exact="hepatitis" post="A, and Japanese encephalitis). Therefore, vaccines that were developed"/>
 <result pre="effective immune response. This approach has been successfully applied to" exact="diphtheria" post="and tetanus, two diseases caused by bacterial toxins (75)."/>
 <result pre="successfully applied to diphtheria and tetanus, two diseases caused by" exact="bacterial" post="toxins (75). Recombinant DNA The development of safer live-attenuated"/>
 <result pre="new approach enabled the generation of the genetically detoxified Bordetella" exact="pertussis" post="toxin (76) and the recombinant hepatitis B surface antigen"/>
 <result pre="the genetically detoxified Bordetella pertussis toxin (76) and the recombinant" exact="hepatitis" post="B surface antigen (HBsAg) (77). Genetic engineering has also"/>
 <result pre="(77). Genetic engineering has also been applied to generate attenuated" exact="viral" post="and bacterial strains as antigen and delivery system for"/>
 <result pre="engineering has also been applied to generate attenuated viral and" exact="bacterial" post="strains as antigen and delivery system for heterologous antigens,"/>
 <result pre="decades, innovative polysaccharides-based vaccines have been developed to protect against" exact="infections" post="caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae"/>
 <result pre="children below 2 years of age and they induced a" exact="short" post="memory response. To enhance immunogenicity, an effective strategy was"/>
 <result pre="that have been efficiently used for the chemical conjugation are" exact="tetanus" post="toxoid (TT), diphtheria toxoid (DT), and a non-toxic cross-reacting"/>
 <result pre="efficiently used for the chemical conjugation are tetanus toxoid (TT)," exact="diphtheria" post="toxoid (DT), and a non-toxic cross-reacting mutant of DT"/>
 <result pre="conjugation are tetanus toxoid (TT), diphtheria toxoid (DT), and a" exact="non-toxic" post="cross-reacting mutant of DT (CRM197). The resulting glycoconjugate vaccines"/>
 <result pre="sites, and (iii) an enzyme covalently coupling both substrates during" exact="bacterial" post="growth. Clinical trials with either mono- and multi-valent vaccine"/>
 <result pre="may play a fundamental role in the future to prevent" exact="infection" post="caused by dangerous AMR pathogens expressing polysaccharide antigens, such"/>
 <result pre="of them, namely AS04, was used in 2005 for the" exact="hepatitis" post="B (HBV) vaccine and in 2007 for the human"/>
 <result pre="A, targeting TLR4), has been licensed for a vaccine against" exact="malaria" post="and herpes zoster vaccine. Also, it is currently used"/>
 <result pre="TLR4), has been licensed for a vaccine against malaria and" exact="herpes zoster" post="vaccine. Also, it is currently used in clinical trials"/>
 <result pre="has been licensed for a vaccine against malaria and herpes" exact="zoster" post="vaccine. Also, it is currently used in clinical trials"/>
 <result pre="H. influenzae and Moraxella catarrhalis, aimed to prevent exacerbation in" exact="chronic" post="obstructive pulmonary disease. The TB vaccine phase 2b trial"/>
 <result pre="and Moraxella catarrhalis, aimed to prevent exacerbation in chronic obstructive" exact="pulmonary disease." post="The TB vaccine phase 2b trial conducted in Kenya,"/>
 <result pre="Kenya, South Africa, and Zambia provided 54.0% protection in M." exact="tuberculosis" post="infected adults against active pulmonary tuberculosis disease. This vaccine"/>
 <result pre="provided 54.0% protection in M. tuberculosis infected adults against active" exact="pulmonary tuberculosis" post="disease. This vaccine is composed of the M72 recombinant"/>
 <result pre="54.0% protection in M. tuberculosis infected adults against active pulmonary" exact="tuberculosis" post="disease. This vaccine is composed of the M72 recombinant"/>
 <result pre="of the M72 recombinant fusion protein including two immunogenic M." exact="tuberculosis" post="antigens (Mtb32A and Mtb39A), combined with the AS01E adjuvant"/>
 <result pre="innate immune receptors have been successfully tested (83). Reverse Vaccinology," exact="Generalized" post="Modules for Membrane Antigens (GMMAs) and Nanoparticles A new"/>
 <result pre="in vaccine design is started through the use of the" exact="bacterial" post="genomes to discover new vaccine candidates. &quot;in silico�? prediction"/>
 <result pre="without using detergents leading to a new generation of improved" exact="bacterial" post="OMVs called generalized modules for membrane antigens (GMMAs). The"/>
 <result pre="mutation in genes responsible for stabilizing the link between the" exact="bacterial" post="outer membrane and peptidoglycan (e.g., tolR, tolB, nlpl). GMMAs"/>
 <result pre="Nanoparticles were initially discovered in virus such as those from" exact="Hepatitis" post="B. Once produced recombinantly these particles were found to"/>
 <result pre="into particles of 24–31 nm diameter resembling the highly immunogenic" exact="viral" post="cores obtained from HBV-infected human liver. Other class of"/>
 <result pre="(94) and of the pre-fusion of F protein of the" exact="respiratory" post="syncytial virus (RSV) (95). Although this approach has been"/>
 <result pre="virus (RSV) (95). Although this approach has been exploited for" exact="viral" post="pathogens, it is expected that the same technologies may"/>
 <result pre="expected that the same technologies may also be applied to" exact="bacterial" post="pathogens. Growing knowledge in this field could lead to"/>
 <result pre="field could lead to rational design of new antigens more" exact="stable" post="and able to elicit high level of functional antibodies."/>
 <result pre="level of functional antibodies. An example of structure-based design of" exact="bacterial" post="antigens is the factor H binding protein (fHbp) of"/>
 <result pre="(96). Monoclonal Antibodies An alternative strategy proposed to combat AMR" exact="infection" post="is based on the use of monoclonal antibodies. The"/>
 <result pre="the neutralization of virulence factor activities and inhibition of complement-mediated" exact="bacterial" post="lysis. An important aspect is that the efficacy of"/>
 <result pre="antibody binding. This is the case of monoclonal antibodies against" exact="bacterial" post="toxins approved for clinical use which include two antibodies"/>
 <result pre="toxins approved for clinical use which include two antibodies against" exact="anthrax" post="(97, 98) and one targeting the toxin B of"/>
 <result pre="toxin B of Clostridium difficile, approved for the prevention of" exact="recurrent" post="infections in high-risk patients (99). As described above, the"/>
 <result pre="B of Clostridium difficile, approved for the prevention of recurrent" exact="infections" post="in high-risk patients (99). As described above, the new"/>
 <result pre="ability to identify, design and stabilize antigens in a very" exact="short" post="time frame and consequently starts clinical trials immediately after"/>
 <result pre="with human tissue at early preclinical stages. Reactions can be" exact="limited" post="by using fully human monoclonal antibodies and by an"/>
 <result pre="More in detail, SAM-based vaccines consist of an engineered RNA" exact="viral" post="genome encoding nonstructural proteins (nsPs) in which the genes"/>
 <result pre="RNA vaccines have shown to be effective in case of" exact="viral" post="pathogens; however, this technology could be successfully applied also"/>
 <result pre="pathogens; however, this technology could be successfully applied also to" exact="bacterial" post="AMR targets. Interestingly, a SAM vaccine encoding for a"/>
 <result pre="island 2a (BP-2a) from Group A (GAS, Streptococcus pyogenes) and" exact="Group B" post="(GBS, Streptococcus agalactiae) was shown to be immunogenic in"/>
 <result pre="mice inducing both humoral and cellular immunity (101). Differently from" exact="viral" post="vectors and DNA -based vaccine, RNA vaccines do not"/>
 <result pre="of expressing complex antigens in large amounts and in a" exact="short" post="time, mRNA technologies could represent a rapid and valuable"/>
 <result pre="may greatly advance the field for the control of AMR" exact="infections" post="(Figure 4). Figure 4 Evolution of vaccine technologies and"/>
 <result pre="vaccine technologies and platforms. MenACWY, meningococcus ACWY; Pneumo, pneumococcus; HBV," exact="hepatitis" post="B virus; Hib, type B Haemophilus influenzae; GBS, group"/>
 <result pre="MenACWY, meningococcus ACWY; Pneumo, pneumococcus; HBV, hepatitis B virus; Hib," exact="type B" post="Haemophilus influenzae; GBS, group B Streptococcus, GAS HPV, human"/>
 <result pre="B; GAS, group A streptococcus; ExPEC, extraintestinal pathogenic E. coli;" exact="Generalized" post="Modules for Membrane Antigens, GMMA. Conclusions and Future Perspectives"/>
 <result pre="burden on healthcare systems. In the European Union, antibiotic resistant" exact="infections" post="determine an economic burden of ~€1.5 billion per year."/>
 <result pre="20 billion USD in excess each year to treat resistant" exact="infections" post="(102). By 2050, it is foreseen that USD100 trillion"/>
 <result pre="infections, the level of transmissibility, the health burden of those" exact="infections" post="and whether alternative treatments are available. AMR can result"/>
 <result pre="available. AMR can result in treatment failures and previously uncomplicated" exact="infections" post="become more complex and severe (103, 104). It has"/>
 <result pre="for surgical procedures and chemotherapy would result in 120,000 additional" exact="infections" post="and 6,300 infection-related deaths per year only in the"/>
 <result pre="protect against serious diseases, vaccines may also reduce avoid mild" exact="disease" post="episodes that may not receive medical attention, but which"/>
 <result pre="attention, but which have important societal consequences. Vaccination decreases the" exact="disease" post="incidence, the number of deaths, the longer hospital stays,"/>
 <result pre="individuals also benefit from wider societal benefits such as the" exact="lower" post="transmission rates. This can be translated into a reduced"/>
 <result pre="reduction in anti-microbial resistance are difficult to measure in the" exact="short" post="term. Therefore, since in the ICUA analysis, the benefits"/>
 <result pre="full vaccine value (105). In 2015, the burden of resistant" exact="infections" post="in countries of the European Economic Area (EEA) was"/>
 <result pre="providing useful information for public health decision-makers prioritizing interventions for" exact="infectious diseases" post="(106). The contribution of various antibiotic-resistant bacteria to the"/>
 <result pre="to fight superbugs. Nature. (2017) 552:165–7. 10.1038/d41586-017-08323-0 5.PlotkinSLPlotkinSA (2013). A" exact="short" post="history of vaccination. Vaccines. 6 edn1–13. 10.1016/B978-1-4557-0090-5.00017-3 6.WohllebenWMastYStegmannEZiemertN. Antibiotic"/>
 <result pre="threats. P T. (2015) 40:277–83.25859123 10.DelanyIRappuoliRSeibKL. Vaccines, reverse vaccinology, and" exact="bacterial" post="pathogenesis. Cold Spring Harb Perspect Med. (2013) 3:a012476. 10.1101/cshperspect.a01247623637311"/>
 <result pre="proportion of bystander selection for antibiotic resistance among potentially pathogenic" exact="bacterial" post="flora. Proc Natl Acad Sci USA. (2018) 115:E11988–95. 10.1073/pnas.181084011530559213"/>
 <result pre="for identification of genetic loci participating in intrinsic susceptibility and" exact="acquired" post="resistance to antistaphylococcal agents. J Antimicrob Chemother. (2013) 68:12–6."/>
 <result pre="isolates from Austrian rivers and clinical isolates from hospitals. Sci" exact="Total" post="Environ. (2019) 662:227–35. 10.1016/j.scitotenv.2019.01.17930690357 24.FrostIVan BoeckelTPPiresJCraigJLaxminarayanR. Global geographic trends"/>
 <result pre="resistance clusters in group B Streptococcus CC17 hypervirulent isolates causing" exact="neonatal" post="invasive disease in southern mainland China. Front Microbiol. (2016)"/>
 <result pre="in group B Streptococcus CC17 hypervirulent isolates causing neonatal invasive" exact="disease" post="in southern mainland China. Front Microbiol. (2016) 7:1265. 10.3389/fmicb.2016.0126527574519"/>
 <result pre="41:130–6. 10.1016/j.ijantimicag.2012.10.01023280442 29.WelteWNestelUWackerTDiederichsK. Structure and function of the porin channel." exact="Kidney" post="Int. (1995) 48:930–40. 10.1038/ki.1995.3748569102 30.LiHLuoYFWilliamsBJBlackwellTSXieCM. Structure and function of"/>
 <result pre="Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant" exact="Bacterial Infections," post="Including Tuberculosis. Geneva:WHO (2017). 39.collab: CDCAntibiotic Resistance Threats in"/>
 <result pre="for Drug-Resistant Bacterial Infections, Including Tuberculosis. Geneva:WHO (2017). 39.collab: CDCAntibiotic" exact="Resistance" post="Threats in the United States. Atlanta, GA: Department of"/>
 <result pre="11:779–88. 10.1517/1465656100359635020210684 41.NasrP. Genetics, epidemiology, and clinical manifestations of multidrug-resistant" exact="Acinetobacter" post="Baumannii. J Hosp Infect. (2019) 104:4–11. 10.1016/j.jhin.2019.09.02131589900 42.GygliSMBorrellSTraunerAGagneuxS. Antimicrobial"/>
 <result pre="of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal" exact="disease" post="in children and adults in the USA: analysis of"/>
 <result pre="Infect Dis. (2015) 15:301–9. 10.1016/S1473-3099(14)71081-325656600 61.CassiolatoAPAlmeidaSCGAndradeALMinamisavaRBrandileoneMCC. Expansion of the multidrug-resistant" exact="clonal" post="complex 320 among invasive Streptococcus Pneumoniae serotype 19A after"/>
 <result pre="antibiotic resistance profiles in children with invasive pneumococcal disease. J" exact="Pediatric" post="Infect Dis Soc. (2017) 6:253–9. 10.1093/jpids/piw00526907814 63.GoldsteinEFinelliLO'HalloranALiuPKaracaZSteinerCAet al.. Hospitalizations"/>
 <result pre="Dis Soc. (2017) 6:253–9. 10.1093/jpids/piw00526907814 63.GoldsteinEFinelliLO'HalloranALiuPKaracaZSteinerCAet al.. Hospitalizations associated with" exact="respiratory" post="syncytial virus and influenza in children, including children diagnosed"/>
 <result pre="66.Rivero-CalleIRaguindinPFGomez-RialJRodriguez-TenreiroCMartinon-TorresFMeningococcal group B vaccine for the prevention of invasive meningococcal" exact="disease" post="caused by Neisseria Meningitidis serogroup B. Infect Drug Resist."/>
 <result pre="(2014) 10:1466–77. 10.4161/hv.2842824637887 68.PoolmanJTAndersonAS. Escherichia Coli and Staphylococcus Aureus: leading" exact="bacterial" post="pathogens of healthcare associated infections and bacteremia in older-age"/>
 <result pre="Coli and Staphylococcus Aureus: leading bacterial pathogens of healthcare associated" exact="infections" post="and bacteremia in older-age populations. Expert Rev Vaccines. (2018)"/>
 <result pre="10.1080/14760584.2018.148859029902092 69.LaceyKAGeogheganJAMcLoughlinRM. The role of Staphylococcus aureus virulence factors in" exact="skin infection" post="and their potential as vaccine antigens. Pathogens. (2016) 5."/>
 <result pre="69.LaceyKAGeogheganJAMcLoughlinRM. The role of Staphylococcus aureus virulence factors in skin" exact="infection" post="and their potential as vaccine antigens. Pathogens. (2016) 5."/>
 <result pre="Microbiol. (2011) 9:889–93. 10.1038/nrmicro266821963800 72.RiedelSEdward Jenner and the history of" exact="smallpox" post="and vaccination. Proc (Bayl Univ Med Cent). (2005) 18:21–5."/>
 <result pre="J Hyg. (1923) 22:208–21. 10.1017/S002217240000817220474806 76.PizzaMCovacciABartoloniAPeruginiMNencioniLDe MagistrisMTet al.. Mutants of" exact="pertussis" post="toxin suitable for vaccine development. Science. (1989) 246:497–500. 10.1126/science.26830732683073"/>
 <result pre="77.van den EndeCMaranoCvan AheeABungeEMDe MoerloozeL. The immunogenicity of GSK's recombinant" exact="hepatitis" post="B vaccine in children: a systematic review of 30"/>
 <result pre="extraintestinal pathogenic Escherichia Coli. in women with a history of" exact="recurrent" post="urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b"/>
 <result pre="27:587–613. 10.1128/CMR.00010-1424982323 89.Petousis-HarrisHPaynterJMorganJSaxtonPMcArdleBGoodyear-SmithFet al.Effectiveness of a group B outer membrane" exact="vesicle" post="meningococcal vaccine against gonorrhoea in New Zealand: a retrospective"/>
 <result pre="of a group B outer membrane vesicle meningococcal vaccine against" exact="gonorrhoea" post="in New Zealand: a retrospective case-control study. Lancet. (2017)"/>
 <result pre="Acad Sci USA. (2018) 115:12887–95. 10.1073/pnas.171716011530559181 91.Al-HalifaSGauthierLArpinDBourgaultSArchambaultD. Nanoparticle-based vaccines against" exact="respiratory" post="viruses. Front Immunol. (2019) 10:22. 10.3389/fimmu.2019.0002230733717 92.Lopez-SagasetaJMalitoERappuoliRBottomleyMJ. Self-assembling protein"/>
 <result pre="al.. Isolation of human monoclonal antibodies that potently neutralize human" exact="cytomegalovirus infection" post="by targeting different epitopes on the gH/gL/UL128-131A complex. J"/>
 <result pre="Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus" exact="infection" post="by targeting different epitopes on the gH/gL/UL128-131A complex. J"/>
 <result pre="3:91ra62. 10.1126/scitranslmed.300223421753121 97.TsaiCWMorrisS. Approval of raxibacumab for the treatment of" exact="inhalation anthrax" post="under the US food and drug administration animal rule."/>
 <result pre="10.1126/scitranslmed.300223421753121 97.TsaiCWMorrisS. Approval of raxibacumab for the treatment of inhalation" exact="anthrax" post="under the US food and drug administration animal rule."/>
 <result pre="10.1177/106002801771302928573869 99.KufelWDDevanathanASMarxAHWeberDJDanielsLM. Bezlotoxumab: a novel agent for the prevention of" exact="recurrent" post="Clostridium difficile infection. Pharmacotherapy. (2017) 37:1298–308. 10.1002/phar.199028730660 100.AndreanoED'OroURappuoliRFincoO. Vaccine"/>
 <result pre="Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding" exact="bacterial" post="antigens. Vaccine. (2017) 35:361–8. 10.1016/j.vaccine.2016.11.04027939014 102.WozniakTMBarnsbeeLLeeXJPacellaRE. Using the best"/>
 <result pre="10.1080/20016689.2017.133516329785252 106.CassiniAHögbergLDPlachourasDQuattrocchiAHoxhaASimonsenGSet al.. Attributable deaths and disability-adjusted life-years caused by" exact="infections" post="with antibiotic-resistant bacteria in the EU and the European"/>
</results>
